Description: PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for intractable cancers, lymphatic and gastrointestinal, central nervous system disorders, and inflammatory and immunological diseases in the United States. The company offers KarXT targeting muscarinic cholinergic receptors to treat schizophrenia and dementia-related psychosis, as well as pain; a superabsorbent hydrogel technology platform to treat excess weight and other chronic diseases related to the gastrointestinal pathways; a digital therapeutics to treat cognitive dysfunction associated with neurology and psychiatry conditions; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a immunomodulation platform to treat chronic and acute inflammatory disorders. It also provides hematopoietic stem cell based therapies to treat hematologic malignancies; a vocal biomarker technology to monitor and diagnose psychological and physical medical conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100, an oral small molecule drug candidate which is in Phase 1 clinical trial to treat lymphedema, and other lymphatic and fibrotic disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210, a IgG1 monoclonal antibody; a synthetic lymphatic targeting chemistry platform; milk exosome-based technology to enable the oral administration of macromolecule therapeutic payloads; and meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases. PureTech Health plc has a collaboration with Boehringer Ingelheim to advance immuno-oncology product candidates. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Home Page: www.puretechhealth.com
PRTC Technical Analysis
6 Tide Street
Boston,
MA
02210
United States
Phone:
617 482 2333
Officers
| Name | Title |
|---|---|
| Ms. Daphne Zohar | Founder, CEO & Exec. Director |
| Dr. Bharatt M. Chowrira J.D., Ph.D. | Pres, Sec., Chief Bus. Fin. & Operating Officer and Exec. Director |
| Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCD | Co-Founder & Non-Exec. Director |
| Dr. Bennett M. Shapiro M.D. | Co-Founder & Board Advisor |
| Dr. David R. Elmaleh Ph.D. | Co-Founder & Sr. Advisor |
| Dr. Joseph B. Bolen | Chief Scientific Officer |
| Ms. Allison Mead Talbot | Head of Communications & Investor Relations |
| Mr. Spencer Ball | Sr. VP of HR |
| Dr. Eric Elenko Ph.D. | Chief Innovation & Strategy Officer |
| Ms. Aleksandra Filipovic M.D., Ph.D. | Head of Oncology |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.7166 |
| Price-to-Sales TTM: | 54.1452 |
| IPO Date: | 2020-11-16 |
| Fiscal Year End: | December |
| Full Time Employees: | 95 |